Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825688 | 0.86 | MAP4K4 (0.37) | MAP4K4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6822495 | 0.85 | MAP4K4 (0.44) | MAP4K4MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6825721 | 0.81 | GRM1 (0.40) | MAPTKDM4EMEN1KMT2ANPC1 | |
| SCHEMBL6825775 | 0.73 | MAP4K4 (0.40) | MAP4K4NT5E | |
| SCHEMBL6822520 | 0.72 | KDM4E (0.43) | MAP4K4NT5EMAPTKDM4EMEN1 | |
| SCHEMBL28015705 | 0.71 | KDM4E (0.38) | MAPTKDM4EMEN1KMT2ANPC1 | |
| SCHEMBL16720191 | 0.69 | KDM4E (0.38) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL3835965 | 0.68 | NPC1 (0.45) | MAPTKDM4EMEN1KMT2ANPC1 | |
| SCHEMBL2165945 | 0.68 | KDM4E (0.38) | MAPTKDM4EMEN1KMT2AADORA3 | |
| SCHEMBL6825816 | 0.68 | GRM1 (0.39) | MAPTKDM4EKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214833-A1 | Tricyclic heteroaromatic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| WO-2004089950-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214833-A1 | Tricyclic heteroaromatic compounds | CYP1A1, SULT2A1, CYP1B1 | MAP4K4 3740/4885NT5E 3299/4885MAPT 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.